The latest update is out from Spero Therapeutics ( (SPRO) ).
Spero Therapeutics, Inc. has released an investor presentation detailing the progress of their diversified clinical-stage portfolio, which includes promising therapies for rare and multi-drug resistant infectious diseases. Their presentation highlighted the development of SPR720, a potential first-line oral treatment for non-tuberculous mycobacterial pulmonary disease, with proof-of-concept data expected in the fourth quarter of 2024. The presentation also covered the anticipated milestones for other assets in their pipeline, such as tebipenem HBr and SPR206, and their strategy for non-dilutive funding alliances. Despite the forward-looking nature of these statements, Spero is keen to keep investors informed on their clinical and commercial potential, while acknowledging the inherent risks and uncertainties in drug development.
See more data about SPRO stock on TipRanks’ Stock Analysis page.
